An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Optinose announces corporate updates and preliminary first quarter 2024 XHANCE net revenue of $14.9 million. The recent FDA approval for a new indication for chronic rhinosinusitis without nasal polyps in patients 18 years and older is a significant milestone. The Company expects peak XHANCE net revenues to exceed $300 million with incremental spend due to leveraging its current commercial infrastructure. They plan to reach an estimated 3 million patients with chronic sinusitis cared for by ENT and Allergy specialists and potentially expand the market opportunity to over 30 million patients by 2025.
Optinose annuncia aggiornamenti aziendali e ricavi netti preliminari per il primo trimestre del 2024 di XHANCE pari a $14,9 milioni. La recente approvazione da parte della FDA di una nuova indicazione per la rinosinusite cronica senza polipi nasali in pazienti di età superiore ai 18 anni rappresenta una pietra miliare significativa. La società prevede che i ricavi netti massimi di XHANCE supereranno i $300 milioni, con spese incrementali grazie all'utilizzo dell'infrastruttura commerciale esistente. Prevedono di raggiungere circa 3 milioni di pazienti affetti da sinusite cronica curati da specialisti in otorinolaringoiatria e allergologia, con la possibilità di espandere l'opportunità di mercato a oltre 30 milioni di pazienti entro il 2025.
Optinose anuncia actualizaciones corporativas y los ingresos netos preliminares del primer trimestre de 2024 de XHANCE, que ascienden a $14.9 millones. La reciente aprobación de la FDA para una nueva indicación para la rinosinusitis crónica sin pólipos nasales en pacientes mayores de 18 años es un hito significativo. La compañía espera que los ingresos netos máximos de XHANCE superen los $300 millones, con un aumento en el gasto debido al aprovechamiento de su infraestructura comercial actual. Planifican alcanzar a aproximadamente 3 millones de pacientes con sinusitis crónica atendidos por especialistas en otorrinolaringología y alergias, y potencialmente ampliar la oportunidad de mercado a más de 30 millones de pacientes para 2025.
옵티노즈는 2024년 1분기 XHANCE 순매출이 1490만 달러로 예비적 결과를 발표하며 회사 소식을 발표했습니다. FDA가 18세 이상 환자의 코에 용종이 없는 만성 부비동염에 대한 새로운 적응증을 승인한 것은 중대한 이정표입니다. 회사는 XHANCE의 최대 순매출이 3억 달러를 넘어설 것으로 예상하며, 현재의 상업 인프라를 활용한 추가 지출이 예상됩니다. 이비인후과 및 알레르기 전문의가 관리하는 만성 부비동염 환자 약 300만 명에게 도달할 계획이며, 2025년까지 시장 기회를 3000만 명 이상으로 확장할 수 있을 것으로 보입니다.
Optinose annonce des mises à jour corporatives et des revenus nets préliminaires de XHANCE pour le premier trimestre de 2024 s'élevant à 14,9 millions de dollars. L'approbation récente par la FDA d'une nouvelle indication pour la rhinosinusite chronique sans polypes nasaux chez les patients de 18 ans et plus représente une étape importante. L'entreprise s'attend à ce que les revenus nets de XHANCE dépassent les 300 millions de dollars, avec des dépenses incrémentielles dues à l'utilisation de son infrastructure commerciale actuelle. Ils prévoient d'atteindre environ 3 millions de patients souffrant de sinusite chronique pris en charge par des spécialistes ORL et des allergologues, et pourraient potentiellement étendre l'opportunité de marché à plus de 30 millions de patients d'ici 2025.
Optinose gibt Unternehmensupdates bekannt und meldet vorläufige Nettoerlöse von XHANCE für das erste Quartal 2024 in Höhe von 14,9 Millionen Dollar. Die kürzliche FDA-Zulassung einer neuen Indikation für chronische Rhinosinusitis ohne Nasenpolypen bei Patienten über 18 Jahre stellt einen bedeutenden Meilenstein dar. Das Unternehmen erwartet, dass die Spitzen-Nettoerlöse von XHANCE 300 Millionen Dollar überschreiten werden, mit zusätzlichen Ausgaben durch die Nutzung der bestehenden kommerziellen Infrastruktur. Sie planen, etwa 3 Millionen Patienten mit chronischer Sinusitis zu erreichen, die von HNO- und Allergiespezialisten betreut werden, und möglicherweise die Marktmöglichkeiten bis 2025 auf über 30 Millionen Patienten zu erweitern.
Positive
None.
Negative
None.
Conference Call and Webcast to be held April 25, 2024, at 10:00 a.m. Eastern Time
YARDLEY, Pa., April 25, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced corporate updates detailing its commercial plans and expectations for XHANCE® (fluticasone propionate) following the recent FDA approval of a new indication for the treatment of chronic rhinosinusitis without nasal polyps in patients 18 year of age and older. The Company will host an investor call at 10:00 a.m. Eastern Time today to discuss its commercial strategy and financial outlook.
In addition, the Company announced preliminary XHANCE net product revenue of $14.9 million for the three months ended March 31, 2024, representing growth of approximately 26% over the first quarter of 2023.
“The recent FDA approval of XHANCE as the first and only approved drug treatment for chronic sinusitis (CS) is a landmark achievement,” said Ramy Mahmoud, MD, MPH, CEO of Optinose. “Because we plan to leverage our current commercial infrastructure, including 75 sales territories, we expect to need limited incremental spend to effectively reach the estimated 3 million patients with chronic sinusitis who are cared for by ENT and Allergy specialists. To prepare for an effective launch, we have recently optimized our sales alignment towards a chronic sinusitis call target universe and partnered with a specialty pharmacy hub to improve patient and physician office experience and increase prescription fill and reimbursement rates. Based on our market analysis, we believe that our base planned efforts focused on a specialty prescriber audience can grow XHANCE peak year net revenues to more than $300 million and allow Optinose to produce positive income from operations (GAAP) for full year 2025. With incremental investments in the future, we believe the market opportunity could be expanded to over 30 million patients through outreach to the 7 million patients being treated by primary care physicians and by direct-to-consumer activation of the 20 million patients who report suffering from chronic sinusitis symptoms,” he concluded.
Financial Outlook:
XHANCE Net Revenue The Company expects peak XHANCE net revenues to exceed $300 million based on its current promotional focus on a specialty audience of mostly ENT and Allergy specialists.
Income from Operations The Company expects to produce positive income from operations (GAAP) for full year 2025.
Company to Host Conference Call Members of the Company’s leadership team will host a conference call to discuss corporate updates. The call is scheduled to start at 10:00 a.m. Eastern Time today.
Participants may access the conference call live via webcast by visiting the Investors section of Optinose’s website at http://ir.optinose.com/event-calendar. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a personal PIN that can be used to access the call. In addition, a replay of the webcast will be available on the Company website for 60 days following the event.
About Optinose Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.com or follow us on X and LinkedIn.
About XHANCE XHANCE is a drug-device combination product that uses the Exhalation Delivery System™ (also referred to as the EDS®) designed to deliver a topical steroid to the high and deep regions of the nasal cavity where sinuses ventilate and drain. XHANCE is approved by the U.S. Food and Drug Administration for both the treatment of chronic rhinosinusitis without nasal polyps (also called chronic sinusitis) and chronic rhinosinusitis with nasal polyps (also called nasal polyps) in patients 18 years of age or older.
IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS: Hypersensitivity to any ingredient in XHANCE. WARNINGS AND PRECAUTIONS:
Local nasal adverse reactions, including epistaxis, erosion, ulceration, septal perforation, Candida albicans infection, and impaired wound healing, can occur. Monitor patients periodically for signs of possible changes on the nasal mucosa. Avoid use in patients with recent nasal ulcerations, nasal surgery, or nasal trauma until healing has occurred.
Glaucoma and cataracts may occur with long-term use. Consider referral to an ophthalmologist in patients who develop ocular symptoms or use XHANCE long-term.
Hypersensitivity reactions (e.g., anaphylaxis, angioedema, urticaria, contact dermatitis, rash, hypotension, and bronchospasm) have been reported after administration of fluticasone propionate. Discontinue XHANCE if such reactions occur.
Immunosuppression and infections can occur, including potential increased susceptibility to or worsening of infections (e.g., existing tuberculosis; fungal, bacterial, viral, or parasitic infection; ocular herpes simplex). Use with caution in patients with these infections. More serious or even fatal course of chickenpox or measles can occur in susceptible patients.
Hypercorticism and adrenal suppression may occur with very high dosages or at the regular dosage in susceptible individuals. If such changes occur, discontinue XHANCE slowly.
Assess for decrease in bone mineral density initially and periodically thereafter.
ADVERSE REACTIONS:
Chronic rhinosinusitis without nasal polyps: The most common adverse reactions (incidence ≥3%) are epistaxis, headache, and nasopharyngitis.
Chronic rhinosinusitis with nasal polyps: The most common adverse reactions (incidence ≥3%) are epistaxis, nasal septal ulceration, nasopharyngitis, nasal mucosal erythema, nasal mucosal ulcerations, nasal congestion, acute sinusitis, nasal septal erythema, headache, and pharyngitis.
DRUG INTERACTIONS: Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. May increase risk of systemic corticosteroid effects.
USE IN SPECIFIC POPULATIONS: Hepatic impairment. Monitor patients for signs of increased drug exposure.
Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this purpose and include, among others, statements relating to: the potential benefits of XHANCE for the treatment of chronic sinusitis (also referred to as "chronic rhinosinusitis" and "chronic rhinosinusitis without nasal polyps"); the Company’s commercial plans and expectations for XHANCE; preliminary XHANCE net revenue for the three months ended March 31, 2024; the Company’s expectation that with only limited incremental spend it can effectively reach the estimated 3 million patients with chronic sinusitis who are cared for by ENT and Allergy specialists; potential market expansion opportunities; the Company’s expectation that it will produce positive income from operations (GAAP) for full year 2025; the Company’s expectation that its base planned efforts focused on a specialty prescriber audience can grow XHANCE peak year net revenues to more than $300 million; and other statements regarding the Company's future operations, financial performance, financial position, prospects, objectives, strategies and other future events. Forward-looking statements are based upon management’s current expectations and assumptions and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: the potential for preliminary XHANCE net product revenue for the three months ended March 31, 2024 to change in connection with the finalization of the Company’s financial results for such period and review by the Company’s independent registered public accounting firm; physician and patient acceptance of XHANCE for its new indication; the Company’s ability to maintain adequate third-party reimbursement for XHANCE (including for its new indication); the prevalence of chronic sinusitis and market opportunities for XHANCE may be smaller than expected; the Company’s ability to efficiently generate XHANCE prescriptions and net revenues; unexpected costs and expenses; the ability to cost-effectively activate XHANCE patients through direct-to-consumer promotion; the Company's ability to achieve its financial outlook; potential for varying interpretation of the clinical trial results of XHANCE; the Company’s ability to comply with the covenants and other terms of the Amended and Restated Pharmakon Note Purchase Agreement; the Company's ability to continue as a going concern; risks and uncertainties relating to intellectual property; and the risks, uncertainties and other factors discussed under the caption "Item 1A. Risk Factors" and elsewhere in the Company’s most recent Form 10-K and Form 10-Q filings with the Securities and Exchange Commission which are available at www.sec.gov. As a result, you are cautioned not to place undue reliance on any forward-looking statements. Any forward-looking statements made in this press release speak only as of the date of this press release, and the Company undertakes no obligation to update such forward-looking statements, whether as a result of new information, future developments or otherwise.
What is the preliminary XHANCE net revenue for the first quarter of 2024?
The preliminary XHANCE net revenue for the first quarter of 2024 is $14.9 million.
What is the recent FDA approval related to XHANCE?
XHANCE received a new indication for the treatment of chronic rhinosinusitis without nasal polyps in patients 18 years and older.
How does Optinose plan to reach patients with chronic sinusitis?
Optinose plans to leverage its current commercial infrastructure, including 75 sales territories, to reach an estimated 3 million patients with chronic sinusitis cared for by ENT and Allergy specialists.
What is the expected peak XHANCE net revenue according to Optinose?
Optinose expects peak XHANCE net revenues to exceed $300 million.
How does Optinose plan to expand the market opportunity for XHANCE?
Optinose plans to potentially expand the market opportunity to over 30 million patients by 2025 through outreach to primary care physicians and direct-to-consumer activation.
